big ideas for global investors Search
   Member Access       Sign-up       Newsfeeds        Companies        Stock Directories       Research       Video       Funding   

Category: Investment, Biotech, Medical Technology

Medical Diagnostic Stock Alert: Decision Diagnostics (OTCBB: DECN) Aims at home testing of blood glucose market with lead product, Shasta Genstrip

Ideas get bigger when you share them...

News about: Decision Diagnostics Corp. (OTCBB:DECN)

New York, New York, Point Roberts, WA - November 19, 2012 ( Newswire), an investor research portal specializing in sector research for independent investors, including Medical Diagnostic stocks, issues an investor snapshot for Decision Diagnostics Corp. (OTCBB: DECN). The Company’s lead product, Shasta Genstrip, is currently in the FDA approval process for at-home testing of blood glucose.

Excerpt from Aug-2012 Quarterly Report

Decision Diagnostics Corp. (OTCBB: DECN) is the parent company of a nationwide prescription and non-prescription diagnostics and home testing products distribution business. The U.S. FDA, in a manner similar to prescription drugs, regulates diagnostic test kits and at-home patient testing products similarly to the regulation of prescription medicine. However, the products we distribute, for the most part, do not require a doctor's prescription for anything other than insurance benefit compliance. Our business model works well in this regulated environment.

We have also continued to ready the company, subject to receipt of an expected FDA 510(k) approval, to introduce a proprietary diagnostic product, the Shasta Genstrip, for at-home testing of blood glucose, an estimated $22.5 billion worldwide market. Shasta Genstrip will compete directly with one of the largest worldwide platform manufacturer for at-home blood glucose testing, a product currently used daily by over 3 million diabetes afflicted Americans. In anticipation of the introduction of Genstrip, currently in the FDA approval process, we have phased out sales of those brand name products that have been a backbone of our current distribution business but will, in the future, would have us compete directly with our Shasta Genstrip product.

Typically, and except for our Shasta Genstrip product, which is an alternative product, we distribute name brand products manufactured primarily by large U.S. and international pharmaceutical companies. The company directs its marketing efforts to ambulatory and semi-ambulatory older Americans afflicted with diabetes and complications caused by diabetes and old age. The company, originally a medical IT company with proprietary IT product lines, acquired its medical products distribution business in late 2004 through a merger with Phoenix, Arizona based CareGeneration, Inc. We have grown the original CareGeneration business through subsequent acquisitions of private businesses and strategic partnerships with larger private pharmacies.

In March 2012 and then again September 2012 representatives of the company and Shasta Technologies LLC met face-to-face with the FDA to ask questions and respond to FDA comments and to present its case in an effort to complete the FDA review process. Subsequently Shasta Technologies LLC and the company have received and responded to a short series of follow up questions and comments by FDA.

Company website

DECN SEC quarterly file

More info on DECN at

About is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.

Follow on Twitter!/Investorideas

Follow on Facebook

Follow News on at

Sign up for the free investor news and stock alerts at

Disclaimer/ Disclosure: The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

Disclosure: has been compensated one hundred fifty thousand shares for news and content publication and distribution for 45 days

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

800-665-0411 - Source -

Free News Alerts

Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner


Investor Ideas © 2000 - 2015®, ECON

Sign up here

login | logout | about us | contact | disclaimer / disclosure |
advertise | company profile directory | partners / links |
job search | privacy policy | trade | services | sitemap |